Shares in Abingdon Health PLC (AIM:ABDX) rose 7% after the contract manufacturer of lateral flow tests said it was cash flow positive in the fourth quarter.
In a trading update, the company reported a 52% increase in annual revenue for the fiscal year ending June 30, reaching £6.1 million.
Second-half revenue grew by 55% compared with the first six months and was ahead 27% year over year. It expects to post a 'solid' performance in the current year.
Abingdon hailed the launch of three new tests under the Boots brand. The acquisition of regulatory consultancy IVDeology in May 2024 further bolstered its service capabilities.
In morning trading, the stock was up 0.67p at 10.67p.